Original Articles
Vol. 7 No. 2 (2018)
https://doi.org/10.4081/ijfs.2018.7242

Effect of Nigella sativa against cisplatin induced nephrotoxicity in rats

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Received: 18 December 2017
Published: 3 July 2018
1624
Views
718
Downloads
204
HTML
Nigella sativa, Renalfunction, Rats.

Authors

Amnah M.A. Alsuhaibani
amalsuhaibani@pnu.edu.sa
Department of Nutrition and Food Sciences, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia.
In this study, the gross composition and mineral content of Nigella sativa seed powder (NSP) and fatty acid composition of Nigella sativa oil (NSO) were investigated. The ability of NSP, extract (NSE) and NSO in reducing the effects of cisplatin-induced renal toxicity in Sprague-Dawley rats were examined. The obtained results showed that NSP contains high amounts of carbohydrates, protein, and fiber while NSO has higher amounts of linoleicacid, oleic acid, and myristic acid. Rats treated with NSP, NSO, and NSE exhibitedreducedserum levels of urea, creatinine, and potassium, and a significant increase of Na, Na/K, vitamin D, nutritional markers, and antioxidant enzymes compared to the cisplatin-induced renal toxicity group receiving no Nigella sativa seed treatment. This study determined that all powder, oil, and extracts of N. sativa contain potent bioactive components that may aid in treatment against cisplatininduced renal toxicity in rats.

Downloads

Download data is not yet available.

How to Cite



1.
Effect of Nigella sativa against cisplatin induced nephrotoxicity in rats. Ital J Food Safety [Internet]. 2018 Jul. 3 [cited 2026 Jun. 20];7(2). Available from: https://www.pagepressjournals.org/ijfs/article/view/7242

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.